Lannett Company, Inc. (NYSE Amex: LCI), a manufacturer of generic pharmaceuticals, today announced the appointment of Paul Taveira to its board of directors, expanding the company’s board to eight members.
Read More

Lannett Company, Inc. (NYSE AMEX: LCI) today reported financial results for the fiscal 2012 third quarter and nine months ended March 31, 2012.
Read More

Lannett Company, Inc. (NYSE AMEX: LCI) today announced that the company will release its fiscal 2012 third-quarter financial results on Tuesday, May 8, 2012 after the market closes.
Read More
Listen To Audio Webcast

Lannett Company, Inc. (NYSE AMEX: LCI) today announced that the company will present at the 24th Annual Roth OC Growth Stock Conference on Monday, March 12, 2012 at 3:30 p.m. PT ( 6:30 p.m. ET) at The Ritz-Carlton Hotel, Laguna Niguel, in Dana Point, California.
Read More
Listen To Audio Webcast

Lannett Company, Inc. (NYSE AMEX: LCI) today reported financial results for the fiscal 2012 second quarter and six months ended December 31, 2011.
Read More

Lannett Company, Inc. (NYSE AMEX: LCI), today announced that it has received approval from the U.S Food and Drug Administration (FDA) of its supplemental Abbreviated New Drug Application (ANDA) for Phentermine HCL Capsules, 15 mg.
Read More

Lannett Company, Inc. (NYSE AMEX: LCI), a manufacture of generic pharmaceuticals, today announced that the company will release its fiscal 2012 second-quarter financial results on Tuesday, February 7, 2012 after the market closes.
Read More
Listen To Audio Webcast

Lannett Company, Inc. (NYSE AMEX: LCI) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA), regarding the design of a Phase III study of the companys Cocaine HCl topical solution product, C-Topical.
Read More